{"id":"gff-mdi-pt-003","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1588467","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PT 003 (GFF MDI) combines glycopyrronium, a long-acting muscarinic antagonist, with formoterol, a long-acting beta-2 agonist, in a single metered-dose inhaler formulation. This dual-action approach provides bronchodilation through two complementary mechanisms: beta-2 agonist-mediated smooth muscle relaxation and muscarinic receptor antagonism, improving airflow and reducing symptoms in obstructive airway diseases.","oneSentence":"GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:56.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT01970878","phase":"PHASE3","title":"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":892}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GFF MDI (PT 003)","genericName":"GFF MDI (PT 003)","companyName":"Pearl Therapeutics, Inc.","companyId":"pearl-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GFF MDI (PT 003) is a small molecule intervention being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is being evaluated in a clinical trial, along with other interventions, to assess its safety and efficacy in patients with moderate to very severe COPD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}